During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple myeloma.
Commentary|Articles|December 6, 2014
Results from the ASPIRE Trial: Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed Multiple Myeloma
Author(s)Shaji Kumar, MD
Shaji Kumar, MD, professor of medicine, Mayo Clinic, discusses the results of the phase III ASPIRE trial.
Advertisement
Clinical Pearls
Shaji Kumar, MD, professor of medicine, Mayo Clinic, discusses the results of the phase III ASPIRE trial.
- This trial looked at the combination of lenalidomide and dexamethasone with or without carfilzomib for patients with relapsed multiple myeloma.
- Adding carfilzomib to lenalidomide and dexamethasone elicited an improvement in PFS.
- The combination was well tolerated.
<<<
Advertisement
Related to this article
During a virtual event, Thomas Martin, MD, and participants considered the use of the on-body injector for subcutaneous isatuximab for a frail patient with transplant-ineligible newly diagnosed myeloma.
Multiple oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
2
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
3
FET-PET, Molecular Testing, and Personalized Treatment Push Brain Tumor Care Forward
4
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
5